Tenascin distribution in human brain tumours

P. Castellani, A. Dorcaratto, A. Siri, L. Zardi, G. L. Viale

Research output: Contribution to journalArticlepeer-review


Using a monoclonal antibody specific for human tenascin (TN), 180 intracranial growths were immunohistochemically studied. In 69 cases of meningioma, neoplastic cells were negative, with some positivity being observed only in the perivascular and the supporting stroma, especially in anaplastic meningiomas. In 57 cases of glioma different degrees of reactivity occurred in both the cellular conglomerates and the stromal components of the tumours. A higher variability in reactivity was observed in anaplastic astrocytomas and glioblastomas. The most constant finding of the study was the staining of the stroma, which was observed in all types of growths, including metastasis, abscess and tuberculoma. The results are consistent with the hypothesis that tenascin is a stromal marker rather than a true marker of malignant tumours. The heterogeneous distribution of TN in anaplastic gliomas may be a factor in the variable response to treatment with radiolabelled anti-TN monoclonal antibodies.

Original languageEnglish
Pages (from-to)44-50
Number of pages7
JournalActa Neurochirurgica
Issue number1-2
Publication statusPublished - Mar 1995


  • Brain tumours
  • immunohistochemistry
  • monoclonal antibody (mAb)
  • tenascin (TN)

ASJC Scopus subject areas

  • Surgery
  • Clinical Neurology


Dive into the research topics of 'Tenascin distribution in human brain tumours'. Together they form a unique fingerprint.

Cite this